STOCKS TELEGRAPH

Tag: $PFE

  • 7 Biotech Stocks to Buy in 2021

    7 Biotech Stocks to Buy in 2021

    Change is inevitable in every aspect of life because it results from human exploration and applying knowledge to improve life quality. This is why many industries have shown significant growth with time, and the biotech industry is one of them. The biotech industry has extraordinarily impacted healthcare, biological science, economy, and business in recent years. The plethora of biotech stocks continuously put their efforts into developing therapeutics and vaccines that are effective and less toxic, and easily accessible for individuals. With the rise of COVID-19, the Biotech industry has gained more importance. Many biotech stocks have developed and commercialize vaccines in the battle against the deadly pandemic. Now many investors are looking for biotech stocks to get high profits in the future. Here are the 7 biotech stocks to buy in 2021.

    Pfizer (PFE)

    The first and foremost stock to watch in 2021 is Pfizer (PFE), one of the first biotech stocks to market the COVID-19 vaccine. Since then, it has contracted with many governments and supplied millions of doses and looking forward to providing more than this in the future. The U.S government has a plan to vaccinate all of its adult population, and Pfizer is likely to contribute a lot to this cause. While many other biotech stocks only focus on older patients, Pfizer is also developing a COVID-19 vaccine for children, which is another positive sign for future growth. The company has a market cap of more than $220 billion and annual revenue of more than $40 billion. Hence Pfizer stock can be a good bet in 2021. 

    Regeneron Pharmaceuticals (REGN)

    The second stock that could prove fruitful for investors in 2021 is Regeneron Pharmaceuticals(REGN). The company has a market cap of more than $55 billion and is engaged in discovering, developing, and manufacturing various therapeutics to treat medical conditions worldwide. One of the two authorized antibody treatments to treat COVID patients belongs to Regeneron. Its recent first-quarter results show that its quarterly revenue showed 38% growth year over year. Its COVID-19 antibody treatment alone generated $262 million in the first quarter of 2021. Besides this, Eylea, a drug to treat eye diseases, also impacts its increased sales over time. Hereafter, investors need to keep an eye on this stock.

    Novavax (NVAX)

    On Number three, we have Novavax (NVAX). It is another biotech stock engaged in the development of commercialization of vaccines to prevent infectious diseases. Novavax has significantly outperformed in the COVID-19 era and still giving a tough time to its competitors. Its COVID-19 vaccine candidate NVX-CoV2373 could bring massive profits in the future. Novavax is about to finalize the major supply deal with the European Union, which means the supply of 500 million or more doses. So, a lot of money on the line is expected for Novavax stock. 

    Moreover, it has also inked supply deals with many countries in which India is also included, which has more than 1.3 billion population. Novavax generated a breathtaking $447 million in revenue in the first quarter of 2021 compared to $3 million in the same quarter of last year. This significantly increased revenue shows its success over the year. In a nutshell, investors should keep an eye on this stock.

    Bio N Tech SE (BNTX)

    On Number four, we have Bio N Tech (BNTX), which is a biotechnology company engaged in discovering and developing therapeutics to treat various infectious diseases. Bio N Tech is the partner of Pfizer in the battle against COVID-19. BNTX stock expects $26 billion in sales for the COVID-19 vaccine and its partner in 2021 and estimates roughly $3 billion in earnings. Millions of the mutually prepared COVID-19 vaccine doses have been delivered to many countries so far. Both partners are negotiating with many other countries to supply COVID-19 vaccine doses worth $3 billion by 2022, which points to the bright future of BioNTech stock. So it can be a good bet for investors in the future.

    Ocugen (OCGN)

    Ocugen (OCGN), stands at number five on our list. It is a clinical-stage biopharmaceutical company focused on developing therapeutics to cure blindness and other retinal diseases. Ocugen stock is working with Bharat Biotech to develop COVAXIN and the vaccine used to treat COVID patients. The phase-3 study results of COVIXIN showed 100% efficacy against severe coronavirus and 78% efficacy against mild and moderate COVID-19 disease. The Indian government has given emergency use authorization to Bharat Biotech which is a positive sign for Ocugen stock. Ocugen stock is looking forward to developing the COVID-19 vaccine for other markets and can be a good bet for investors in the future.

    Seagen (SGEN) 

    Seagen Inc is an American-based biotech stock focused on developing and commercializing therapeutics to treat cancer patients, and it’s in the Number six position on our list. Seagen has shown significant growth in 2020 as compared to 2019. Its revenue for 2020 totaled $2.2 billion, which shows 140% growth over the year. The revenue for the year 2019 was $916.7 billion. The company has achieved global success with Adcetris, an antibody medicine used to treat lymphoma, and is in an excellent position to invest more in developing newer medications. Therefore, Seagen is one of the biotech stocks to watch in 2021.

    Vertex Pharmaceuticals (VRTX)

    The seventh biotech stock to watch in 2021 is Vertex Pharmaceuticals Incorporated (VRTX), which is mainly focused on developing and commercializing therapeutics to treat cystic fibrosis. Trikafta is the most important drug of Vertex pharmaceutical that treats roughly 90% of patients with cystic fibrosis. Estimates show that 70,000 cystic fibrosis patients are there globally, and Trikafta is the only medication available for this disease. Vertex stock has generated significant revenue through Trikafta and some other products, which will continue to rise in the future. The company has partnered with CRISPR Therapeutics and announced impressive results from a clinical trial of gene therapy for two rare blood diseases. Consequently, its continued success against cystic fibrosis and clinical developments suggests that this stock could outperform in the long run.

    The following three biotech stocks are with the lowest 12-month trailing price-to-earnings ‎ratio (P/E). Dividends and buybacks are two ways a company can return profits to ‎shareholders, so a low P/E ratio shows you are paying less for every dollar of profits ‎generated.

    The Agios Pharmaceuticals (AGIO)‎

    The Agios Pharmaceuticals Inc. platform is a pharmaceutical company dedicated to ‎developing drugs for genetic diseases such as hemolytic anemias and sickle cell disease. In Q1 ‎‎2021, the company reported a net income of $1.9 billion, a far cry from its Q1 2020 loss. ‎Agios’ oncology portfolio was sold to Servier Pharmaceuticals LLC in the first quarter, which ‎had an impact on revenue.

    Sage Therapeutics, Inc.. (SAGE)

    Sage Therapeutics has developed treatment for issues related the central nervous system, including schizophrenia and major depression. The company reported positive results from its SAGE-718 clinical trial, a drug that may be used to treat Huntington disease, in Q1 2021.

    Innoviva Inc. (INVA)

    Innoviva is a healthcare-oriented asset manager that holds portfolios of royalties for many pharmaceuticals.

  • Early Morning Vibes: Check Out These 4 hot Stocks Right Now

    Early Morning Vibes: Check Out These 4 hot Stocks Right Now

    On February 1, the American stock exchanges finished trading in the green zone. The S&P 500 Index climbed 1.61% to 3774 points, the Dow Jones added 0.76% and the NASDAQ rose 2.55%. Fears about the impact of short squeezes on the market have slightly subsided, and quarterly reports and macro statistics returned to the focus of investors’ attention. The cyclical consumer goods sector topped the broader market, gaining 2.77% on positive gains from Amazon and Tesla. The tech sector also outperformed the market, adding 2.51%.

    Corporate Details

    Ford (F: + 2.9%) announced a strategic partnership with Google (GOOGL: + 3.6%) for EV software.

    ON Semiconductor (ON: + 6.4%) came out better than expected, mainly driven by the automotive components segment.

    Virgin Galactic (SPCE: + 21.5%) announced plans to test launch its SpaceShipTwo Unity rocket after February 13.

    Today world stock exchanges are showing positive dynamics. Recovery of quotations after a sharp drop last week continues. President Biden discussed with a group of Republicans the stimulus package. Negotiations have made little progress, but GOP officials said Biden is willing to make concessions on some points of the program. The president has not yet rejected the possibility of a “reconciliation” procedure, through which a package of $ 1.9 trillion can be passed through a simplified vote in Congress, even without the support of the Republicans.

    Concerns about the impact of short squeezes on the market were largely eliminated by the comments of investment banks, which noted the presence of numerous factors favorable for the development of an upward trend, including a strong reporting season. Due to the effect of inflated expectations, the shares of many reported companies corrected, but a positive reaction may follow with some delay.

    The Freedom Finance Sentiment Index remains at 68 out of 100. The index reflects market participants’ hope for a global economic recovery in 2021. Concerns about the negative impact of the coronavirus pandemic are gradually diminishing thanks to the prospect of mass vaccinations.

    Technical picture

    Technically, the S&P 500 is still bullish in the medium term. The day before, the broad market index bounced off the 50-day moving average, at the level of which buying activity intensified. In the short term, consolidation is likely, as the RSI indicator is in the neutral zone and indicates the equality of forces between the “bulls” and “bears”.

    Today Top Movers

    ‎Prothena Corporation plc (PRTA) share price jumped 29.55% to $14.25 during the early morning ‎trading session on ‎Tuesday after declaring confirmatory phase 3 AFFIRM-AL study of Birtamimab in mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA.‎
    ‎ ‎‎
    ‎Nio Inc (NIO) stock ascended 1.09% at $57.61 in the pre-market trading today.‎ after the company provides January 2021 Delivery update.
    ‎ ‎‎
    ‎GoPro Inc (GPRO) gained over 8.17% at $11.39 in pre-market ‎trading on Tuesday.‎ ahead of its earnings scheduled on 4 Feb.
    ‎ ‎‎
    ‎Virgin Galactic Holdings Inc (SPCE) grew over 10.04% at $59.19 in pre-market trading ‎today. The company recently revealed the date of its new flight window for a rocket-powered test flight of its SpaceShipTwo Unity.‎

    Top Upgrades & Downgrades

    Evercore ISI Group turned bullish on TETRA Technologies Inc. (TTI), upgrading the stock to “Outperform” and assigning a $3.0 price target. 

    Dell Technologies Inc. (DELL) has won the favor of B of A Securities’ equity research team. The firm upgraded the shares from Neutral to Buy and moved their price target to $80.0, suggesting 29.73% additional upside for the stock. 

    Rio Tinto Group (RIO) received an upgrade from analysts at Credit Suisse. They changed their rating on RIO to Outperform from Neutral in a recently issued research note. 

    Earlier Tuesday Piper Sandler reduced its rating on argenx SE (ARGX) stock to Neutral from Overweight and assigned the price target to $303. 

    Cowen analysts reduced their investment ratings, saying in research reports covered by the media that it’s rating for Limelight Networks Inc. (LLNW) has been changed to Market Perform from Outperform and the new price target is set at $4.75. 

    Analysts at Compass Point downgraded Hilltop Holdings Inc. (HTH)’s stock to Neutral from Buy Thursday.

    Latest Insider Activity

    Inovio Pharmaceuticals Inc. (INO) Chief Operating Officer Shea Jacqueline Elizabeth announced the sale of shares taking place on Jan 28 at $12.04 for some 16,713 shares. The total came to more than $0.2 million. 

    DuPont de Nemours Inc. (DD) President, T&I Stone Randy Lee sold on Jan 28 a total of 30,622 shares at $79.97 on average. The insider’s sale generated proceeds of almost $0.25 million. 

    VYNE Therapeutics Inc. (VYNE) 10% Owner PERCEPTIVE ADVISORS LLC declared the purchase of shares taking place on Jan 28 at $2.37 for some 4,219,409 shares. The transaction amount was around $10.0 million. 

    Alcoa Corporation (AA) Director Nevels James E bought on Jan 27 a total 32,336 shares at $17.50 on average. The purchase cost the insider an estimated $7,000.

    Important Earnings

    Top US earnings releases scheduled for today include Pfizer Inc. (NYSE: PFE). It will announce its Dec 2020 financial results. The company is expected to report earnings of $0.48 per share from revenues of $11.43B in the three-month period. 

    Analysts expect Alibaba Group Holding Limited (NYSE: BABA) to report a net income (adjusted) of $3.25 per share when the bank releases its quarterly results shortly. Revenue for the fiscal quarter ended Dec 2020 is predicted to come in at $33.35B. 

    Amazon.com Inc. (AMZN), due to announce earnings after the market closes today, is expected to report earnings of $7.23 per share from revenues of $119.7B recently concluded three-month period.

  • Pfizer Inc. (NYSE: PFE) set to roll out 50 million coronavirus vaccines by the end of 2020

    Pfizer Inc. (NYSE: PFE) set to roll out 50 million coronavirus vaccines by the end of 2020

    Drug-maker giant Pfizer Inc. (NYSE: PFE) shares jumped 14% after it said that preliminary analysis showed 90% efficacy of its coronavirus vaccine.

    It was called a “great day for science & humanity,” by development companies Pfizer and BioNTech.

     

    Their vaccine was tested in six countries on 43,500 individuals and no safety issues were posed.

    In response to a clear end to the US election, stocks, already bolstered, poured on profits and the FTSE 100 soared 5 percent.

     

    But businesses benefiting from it dived as airlines, hotels, and others hit hardest by the pandemic jumped by up to 53 percent.

     

    Similar gains to those seen in London were made by other markets in Europe. And the Dow Jones and S&P 500 opened 5.6% and 3.6% higher, respectively, in the US.

     

    It is very unusual for stocks to leap by such wide margins, and in the case of the UK, on the market’s best day since March, the FTSE 100 added £82bn to the value of its shares.

     

    Companies expect to apply by the end of the month for emergency permission to use the vaccine.

     

    There is still a lot of work to be done, but the news was warmly embraced by scientists who are anticipating that by spring life could be back to normal.

     

    A vaccination is seen as the only way to break out of the constraints that have been placed in the daily lives, alongside improved therapies.

     

    In the final stages of study-known as a phase 3 trial-there are around a hundred, but this is the first to produce any results.

     

    In order to train the immune system, it uses an entirely experimental technique-which includes injecting part of the genetic code of the virus.

    Previous studies have shown that the body is being prepared to generate both antibodies and another element of the immune response against coronavirus called T-cells.

     

    This drug is injected in two doses, three weeks apart. Studies in the United States, Germany, Brazil, Argentina, South Africa, and Turkey have shown that 90% of safety is obtained 7 days after the second dose.

     

    Pfizer in the meantime plans to produce 50 million doses by the end of this year and about 1.3 billion by the end of next year.

     

  • Is Pfizer Inc. (NYSE: PFE) A Good Investment?

    Is Pfizer Inc. (NYSE: PFE) A Good Investment?

    Shares of Pfizer Inc. (NYSE: PFE) traded up 2.61% after gaining +0.94 on Monday as it may be the first to disclose the late-stage study result from its trials with partner BioNTech SE. Pfizer Inc. is currently conducting one of the most advanced trials of a vaccine for novel coronavirus.

    It has commenced the Phase 2/3 study of BNT162b2, a most advanced coronavirus vaccine candidate in July. Almost 30,000 participants were enrolled in the trial who received two doses of the vaccine candidate.

    Pfizer CEO Albert Bourla revealed that the FDA committee will gather to discuss vaccines on Oct 22. CEO said that the company has a deep understanding of this matter and it will be able to present the efficacy data of Phase 3 before the end of October.

    He said that the company is not bound to any deadline. Albert Bourla said that FDA is searching for companies to review their vaccines that are at least 50% effective. Pfizer is hoping for a better result as its Phase 3 trial with 30,000 people is almost completed.

    Goldman Sachs labeled this a vaccine trade as the investors were attracting towards stocks that were developing a vaccine or any treatment of diseases and they dumped the stock soon after hearing the good news. The same thing happened with Gilead Sciences as its shares tumbled down after it has got the regulatory approval for its antiviral medicine of COVID-19.

    Pfizer Inc. (NYSE: PFE) share price went from a low point around $27.88 to briefly over $40.97 in the past 52 weeks, though shares have since pulled back to $37.01. Pfizer Inc. has moved up 32.75% from its 52-weeks low and moved down -9.67% from its 52-weeks high. Pfizer Inc.’s market cap has remained high, hitting $203.27 billion at the time of writing. If we look at its liquidity, it has a current ratio of 1.40.

    Pfizer Inc and BioNTech SE have recently disclosed that they striving to secure the approval of the US FDA to expand the late-stage clinical trial of their COVID-19 vaccine. Earlier, Pfizer has enrolled the 30,000 participants in the trial but now it is looking for the trial which will enroll 44,000 volunteers as the company is trying to add the young population in the late-stage study.

    Previously, the US Government has revealed that it would pay $1.95 billion to companies for the supply of 100 million doses of vaccine if it received regulatory approval. CEO Pfizer also disclosed that the company has invested $1.5 billion for the development of a vaccine and if the trial is not successful it is painful for the company.